Evidence map›Paper›PMID 27483410›Full record

Trial reportArthritis & rheumatology (Hoboken, N.J.)2017

Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.

Christina Charles-Schoeman, Yuen Yin Lee, Ani Shahbazian, Xiaoyan Wang, David Elashoff, Jeffrey R Curtis, Iris Navarro-Millán, Shuo Yang, Lang Chen, Stacey S Cofield and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christina Charles-SchoemanUniversity of California, Los Angeles.
Yuen Yin LeeUniversity of California, Los Angeles.
Ani ShahbazianUniversity of California, Los Angeles.
Xiaoyan WangUniversity of California, Los Angeles.
David ElashoffUniversity of California, Los Angeles.
Jeffrey R CurtisUniversity of Alabama at Birmingham.
Iris Navarro-MillánUniversity of Alabama at Birmingham.
Shuo YangUniversity of Alabama at Birmingham.
Lang ChenUniversity of Alabama at Birmingham.
Stacey S CofieldUniversity of Alabama at Birmingham.
Larry W MorelandUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Harold PaulusUniversity of California, Los Angeles.
James O'DellUniversity of Nebraska Medical Center, Omaha.
Joan BathonColumbia University, New York, New York.
S Louis BridgesUniversity of Alabama at Birmingham.
Srinivasa T ReddyUniversity of California, Los Angeles.

Funding

UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid ArthritisR01HL123064 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2015 to 2019
$2.7M
Longitudinal Comparative Effectiveness & Safety of Biologics in AutoimmunityR01HS018517 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURTIS, JEFFREY R. · 2009 to 2013
$2.2M
Predictors of Treatment Response in Early Aggressive RAR01AR052658 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRIDGES, S LOUIS · 2004 to 2007
$1.2M
Ethnic Differences in the Risk of Fracture and Vascular DiseaseK23AR053351 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURTIS, JEFFREY R. · 2007 to 2011
$755k
HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid ArthritisK23HL094834 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2009 to 2013
$693k
Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?R21AR057913 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA, REDDY, SRINIVASA T. · 2010 to 2011
$384k
AHRQ HHS R01 HS018517NCRR NIH HHS UL1 RR033176NHLBI NIH HHS K23 HL094834NHLBI NIH HHS R01 HL123064NIAMS NIH HHS K23 AR053351NIAMS NIH HHS R01 AR052658NIAMS NIH HHS R21 AR057913
6 · The paper itself

Abstract

objectiveAbnormal function of high-density lipoprotein (HDL) has been implicated as a potential mechanism for the increased incidence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA). This study was undertaken to evaluate changes in HDL function and HDL-associated proteins over 2 years of follow-up in patients with early RA receiving either methotrexate (MTX) monotherapy, MTX + etanercept (ETN) combination therapy, or MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.

methodsThe antioxidant capacity of HDL, paraoxonase 1 (PON-1) activity, and levels of HDL-associated haptoglobin (Hp), HDL-associated apolipoprotein A-I (Apo A-I), and myeloperoxidase (MPO) were measured in 550 TEAR participants at 4 time points (time 0 [pretreatment] and at 24, 48, and 102 weeks of treatment). Repeated-measures analysis using mixed-effects linear models with an autoregressive covariate structure was performed to model the within-subject covariance over time.

resultsMixed-effects models, which were controlled for traditional CV risk factors, treatment regimen, prednisone use, and statin use, demonstrated significant associations between RA disease activity, measured using the Disease Activity Score in 28 joints, erythrocyte sedimentation rate, or C-reactive protein level, and the profile of HDL function over time. Specifically, decreases in RA disease activity over time were associated with increases in PON-1 activity and levels of HDL-associated Apo A-I, and decreases in the HDL inflammatory index and levels of MPO and HDL-associated Hp.

conclusionReduced disease activity in patients with early RA treated with MTX monotherapy, MTX + ETN combination therapy, or MTX + SSZ + HCQ triple therapy in the TEAR trial was associated with improvements in the HDL function profile. Additional studies are warranted to evaluate abnormal HDL function as a potential mechanism and therapeutic target for CV risk in patients with RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDrug Therapy, CombinationEtanerceptFemaleHumansHydroxychloroquineLipoproteins, HDLMaleMethotrexateMiddle AgedSulfasalazineAntirheumatic AgentsEtanerceptHydroxychloroquineLipoproteins, HDLMethotrexateSulfasalazine

Identifiers

PMID27483410
PMCPMC5195879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.